Overview

A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes

Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study will investigate how the body processes nasal glucagon and the effect of nasal glucagon on the body. After an 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, the study drug will be delivered into the participant's nostril(s) (intranasally) once or twice in each of four study periods. The study is open to adults with type 1 or type 2 diabetes and is expected to last about 50 days for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Locemia Solutions ULC
Treatments:
Glucagon